Versant invests again in obesity, this time backing Helicore Biopharma

Versant Ventures has made its fourth investment in an obesity startup in eight months, co-leading a $65 million Series A round in Helicore Biopharma, a developer of an antibody drug that blocks a gut hormone tied to hunger and blood sugar levels.